News 
Market Data 
Discover
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I have the patients to wait this out 2025 should be a golden year. I do expect an offering after FDA approval to cushion the company for US commercial launch and future success.
https://www.icecure-medical.com/
Summer Biz presentation:
https://d1io3yog0oux5.cloudfront.net/_7548b0974a425145cf30e73983d71f6b/icecuremedical/db/2291/21959/pdf/IceCure+Company+Presentation+-+June+2024+-+Final+Clean.pdf
$ICCM
Need to be patient hold the line! FDA panel meeting on Approval is set for November so Late q4 2024 early Q1 2025 USA FDA approval should happen for early stage breast cancer patients and then 12 months from Japanese application which is set to in by Q1 2025 so we should get approval in late 2025 early 2026 for Japanese Approval Only hiccup for USA approval would be a CRL on manufacturing of the device but not likely USA approval should be a slam dunk in my opinion.
$ICCM
Timing is everything. Fortunes will be made. Mic drop!
$ICCM
I'm a buyer at .72 cents recently.
You got to see the angles before they are played.
What a solid day in a sea of red.
Most undervalued stock I have come across in years.
$ICCM
I hope the anti israel investor shorts this with dark pool trades I want to squeeze them to the poor house.
Sales should start ramping up soon.
$ICCM
This company deserves Billion dollar plus market cap=$20.00+ I did the research for you. Talked to management and have commenced talks with other companies in the medical device space to buy them.
CURES CANCER by Freezing and Killing Tumors organically.
The clowns trying to manipulate the price are going to get hit by the IceCure train!
Next Level technology company from Israel.
Only so many shares floating the ATM is being used only when it needs to be! $4 million in quarter one is modest.
$ICCM
This is just the start. I gave you guys ample time to get in at the basement discount fire sale prices. This stock will hit multiple dollars and eventually $10.00+ don't sleep on it.
$ICCM
$10.00 Stock
I think a company like Pulse Bio sciences Love to see Duggan scoop it up. I talked to Pulse management last week and explained that ICCM would be a great compliment to their umbrella of minimally invasive medical device technology. I believe a medium to large cap medical device company or pharma company buys out IceCure.
260k shares average price .72
I will lead you to Victory!
Core Holding!
$ICCM
Cures 97% of early breast cancer patients after 5 year follow up independent study.
Published in highly recognized medical journal.
92% Cure rate for Late stage Breast cancer patients with large Tumors
IceCure Medical's ProSense Cryoablation System
Cures 97% of early breast cancer patients after 5 year follow up independent study.
Published in highly recognized medical journal.
92% Cure rate for Late stage Breast cancer patients with large Tumors
FREEZING CANCER IN ITS TRACKS.
The Lee Family one of Asia Richest familes owns 52% of ICCM
Independent Study Results in Japan Demonstrate Zero (0%) Breast Cancer Local Recurrence 5 Years Following Treatment with IceCure's ProSense®, Adding to Continued Positive Data Published Globally.
Study published in the peer reviewed journal Breast Cancer.
Excellent cosmetic outcomes, high degree of patient satisfaction, and improved quality of life post-cryoablation
Strategic distribution partner of ProSense® in Japan, Terumo Corporation, expects to submit an application for regulatory clearance for breast cancer in the second half of 2024
https://ir.icecure-medical.com/news-events/press-releases/detail/126/independent-study-results-in-japan-demonstrate-zero-0-breast-cancer-local-recurrence-5-years-following-treatment-with-icecures-prosense-adding-to-continued-positive-data-published-globally
[color=red]
https://ir.icecure-medical.com/news-events/press-releases/detail/134/european-study-provides-more-evidence-supporting-icecures-prosense-is-safe-effective-cryoablation-treatment-for-metastatic-and-recurrent-breast-cancer
IceCure applications: Breast Cancer early and Late Stage, Kidney Lung, Liver Cancer, Pain, and Palliative Care, Fibroadenoma Kills bad fat cells (Obesity) application on tap!
https://www.icecure-medical.com/clinical-applications/
Recap IceCure no surgery in patient setting local anesthetic insurance companies have signed on. no radiation treatment! natural freezing that kills cancer tumors for early stage breast cancer with 97% success rate after 5 Years! This is expanding with late stage breast cancer wide array of oncology indications and large tumors. Lung, Kidney and Liver Cancer Approved in 15 countries and counting sales ramping up no debt or warrants.
Summer IceCure Biz Presentation.
https://d1io3yog0oux5.cloudfront.net/_bff00726f3fc2e5c631f07f65bc0c3de/icecuremedical/db/2291/21959/pdf/IceCure+Company+Presentation+-+June+2024+-+Final+Clean.pdf
$ICCM[/color]
Cures Cancer
Early Breast Cancer after 5 year follow up 97% complete response rate for early stage breast cancer independent studies completed in multiple countries.
Highly acclaimed peered reviewed journal.
Late stage Breast cancer Data is 92% complete response rate.
ICE3 Trial - Positive Final Results
96.3% Free from local recurrence for patients treated with ProSense® Cryoablation.
100% Safe Procedure
No significant device-related adverse events or complications have been reported.
100% Doctor & Patient Satisfaction with ProSense® Procedure.
No scarring or change to the shape and size of the breast.
Billionaire owns 52% of the shares from one of the wealthiest families
Cryoablation minimally invasive no drugs needed to put the patient out only local anesthetic and the patient is home in two hours no stitches. No surgery no radiation This is very disruptive to the Cancer Space.
Approved in 15 countries.
I have been accumulating shares daily and will continue. Potential to break $10.00 and new highs. I bought PLSE at $1.30 and rode half my shares into the high teens!
Cryoablation is treating Kidney, Bone, Lung and Liver cancer and Palliative care interesting there could be an obesity angle as well as the Freezing temps kills tumors and bad fat cells.. Non Invasive Medicine is growing and as we go move forward in medicine these area of medicine will grow leaps and bounds.
Harvard Health Blog The skinny on freezing fat
https://www.health.harvard.edu/blog/the-skinny-on-freezing-fat-2020031218990#:~:text=Average%20reduction%20in%20fat%20ranges,depending%20on%20the%20desired%20results.
IceCure Medical's ProSense Cryoablation System
Independent, third-party data published in highly influential peer-reviewed journal, Cancers, concluded cryoablation with ProSense® is a safe, local treatment for early and late stage breast cancer with tumors big and small with non complication rate, high complete ablation rate and satisfactory overall survival (OS), progression free survival (PFS) and
local tumor control 5 year early breast cancer data success rate 97% late stage breast cancer with larger tumors nearly 93% success rate. This is the closest thing in breast cancer to a Cure and best in class results with local local anesthetic vs anesthesia in a surgery setting with 15-20% of lumpectomy patients need to go back for second surgery. This stock has a Billion dollar plus market cap potential by end of next year.=3000% upside if Pulse Bio Sciences did it from the low 1.00 range from 2 years ago and a 50 million dollar market cap a few years to a Billion dollar market cap today.
Both companies have large insider ownership Sales will ramp up for IceCure in the coming quarters.
$ICCM
IceCure Medical's ProSense Cryoablation System (next Frontier in cancer medicine)
Cancer Cure for early stage breast cancer 97% success rate with 5 year follow up independent data.
Approved in 15 countries
Late stage Breast cancer is showing best in class data with large tumor destruction with nearly 93% success rate for late stage breast cancer patients with 1 year follow up. The company is working on a wide array of cancer applications.
Oncology Indications
https://www.icecure-medical.com/clinical-applications/
Freezing Cancer in its Tracks IceCure Medical, enabling non-surgical treatment of cancerous tumors.
Billionaire Victor Lee owns 52% of the ICCM shares a man who help built Tencent into one the most successful tech companies in Asia. Comes from one of the richest families in Asia.
2024 June Presentation.
https://d1io3yog0oux5.cloudfront.net/_5a446bd24270711d45714fda93e00997/icecuremedical/db/2291/21959/pdf/IceCure+Company+Presentation+-+June+2024+-+Final+Clean.pdf
Dr. Belinda Barclay-White on Breast Tumor Cryoablation.
Cryoblation ice crystals Killing breast cancer tumors and dead fat. Ice3 Trial 5 year follow up killing 98% of small breast cancers better than surgery also has Data on later stage breast cancers with tumors twice the size as earlier studies with a 93% success rate for late stage Breast cancers.. .
IceCure Medical's Breast Cryoablation Gains Prominence in the U.S., as Society of Interventional Oncology Annual Meeting Features its First Breast Cryoablation Master Class
https://www.prnewswire.com/news-releases/icecure-medicals-breast-cryoablation-gains-prominence-in-the-us-as-society-of-interventional-oncology-annual-meeting-features-its-first-breast-cryoablation-master-class-302046623.html
[color=red]
Cryoablation Takes Center Stage at American Society of Breast Surgeons' 24th Annual Meeting.
IceCure's ProSense was the cryoablation system used in first-of-its-kind cryotherapy continuing medical education (CME) course.
High level of interest expressed in cryoablation from attending surgeons and from American Society of Breast Surgeons (ASBrS) leadership.
Plan presented for a proposed ASBrS Cryoablation trial during CME course.
https://ir.icecure-medical.com/news-events/press-releases/detail/81/cryoablation-takes-center-stage-at-american-society-of-breast-surgeons-24th-annual-meeting
Home Media and publications Media Archive SIR 2024 breast cancer
A minimally invasive technique that uses ice to freeze and destroy small, cancerous tumors has now been proven effective for breast cancer patients with large tumors, providing a new treatment path for those who are not candidates for surgery, according to new research to be presented at the Society of Interventional Radiology Annual Scientific Meeting in Salt Lake City.
https://www.sirweb.org/media-and-pubs/media/news-release-archive/sir-2024-breast-cancer-032024/
Choose the Power of Liquid Nitrogen Cryoablation for a Wide Range of Clinical Applications[/color]
https://www.icecure-medical.com/clinical-applications/
June 2024 ICeCure Biz Presentation.
https://d1io3yog0oux5.cloudfront.net/_5a446bd24270711d45714fda93e00997/icecuremedical/db/2291/21959/pdf/IceCure+Company+Presentation+-+June+2024+-+Final+Clean.pdf
$ICCM
Victor Li, head of one of Hong Kong’s oldest business empires And from one of the richest families in China, has been busy forging partnerships with a slew of mainland Chinese technology companies including (Tencent 3.60 trillion Hong kong dollars) to modernize CK Group including deals after taking over the conglomerate earlier this year.
$ICCM
Victor Li owns over 52% of ICCM
$PLSE was about 1.30 a few years ago to a high of $17.00 this year and their majority owned by Bob Duggan and the company went from a 50 Million market cap to over a billion dollar market cap in no time.
ICCM has massive upside When it breaks $2.00-$10.00+ will happen its all in the charts!.
Very honored to have Vic Li, our leading shareholder and his associate, Yankor Huang, visit the IceCure offices today and see our #LN2 #cryoablation technology in action. Thank you for your continued belief and support in us!
Victor Lee the Business tycoon has been an active major shareholder for 9 years.
https://www.facebook.com/IceCureMedical/posts/2448349238625488/
Bob Duggan thinking about buying IceCure? Fits his ethos to a tee. He's worth about 6 Billion dollars.
The trend of minimal/non invasive technologies not needing surgery is growing substantially from patients to doctors and insurance companies and rain makers like Duggan and many others. The new paradigm of medicine is starting to change at an accelerated pace. ICCM exceptional data now showing treatment for later stage breast cancers with bigger tumors is game changing for IceCure. And displaying remarkable data results for Lung, Kidney, Bone Cancer. Taking a local anesthetic being able to go home in a few hours with no scaring most important the results of IceCure Patients and Doctors are nearly 100% satisfied. Killing cancer by Freezing it in it's tracks with 5 year follow up studies in early breast cancer patients and highly showcased in a highly acclaimed peer reviewed publication approved in 15 countries and the list is growing.
$ICCM
Independent Studies Confirm ICE3 Results
In women with early-stage breast cancer who
declined surgery.
Study conducted by Principal Investigator Lucía Graña-López,
MD, PhD, a radiologist who specializes in breast and women's
imaging, Head of the Breast Unit at University Hospital Lucus
Augusti, Spain—presented at European Society of Breast Imaging Annual Scientific Meeting 2023 96.8% Success rate.
93.4% - 96.8%
Tumor reduction rate
In women deemed inoperable for breast cancer.
Breast Cancer – U.S. Healthcare Economics &
Reimbursement
Healthcare Economics: Cryoablation costs less than standard-of-care lumpectomy and
further reduces costs by reducing risk of re-excision as compared to lumpectomy1
Reimbursement:
Demonstrating its leadership in cryoablation, IceCure is the first company to apply for and
receive Medicare coverage for breast cancer cryoablation through the Centers for Medicare & Medicaid
Services (CMS)
CMS assigned CPT Category III 2 Breast/Lymphatic Surgery and Related Procedures
Priced for coverage by the CMS at approximately $3,400 for the facility fee alone
Additional coverage, including payment for the physician, is expected upon establishment of the
permanent CPT Category I 2 code
Patient demand drives reimbursement.
Large insider buys a few weeks ago 57% of the stock is Insider Owned.
21 Million shares Floating
No warrants no debt no history of reverse splits.
$ICCM
Killing Cancer Tumors by Freezing them new paradigm in medicine.
Growing number of global distribution agreements. More to come!
Insurance Reimbursement: CPT III for breast cancer cryoablation facility fee established.
51 IP Patents
Excellent patient & physician feedback.
Peer Reviewed Journal completed.
Data displaying next level treatment for early and now late stage cancer patients with larger tumors.
Independent clinical trials are investigating the use of cryoablation in the treatment of endometriosis; a condition that impacts over 6.5 million women in the U.S.
Best in Class data displayed in Breast Cancer, Lung Cancer, Bone Cancer, Kidney Cancer.
Growing cancer burden Increasing demand for non/minimal-invasive solutions Push for reduced cost of care by insurers & payers.
June 2024 IceCure Biz Presentation.
https://d1io3yog0oux5.cloudfront.net/_5a446bd24270711d45714fda93e00997/icecuremedical/db/2291/21959/pdf/IceCure+Company+Presentation+-+June+2024+-+Final+Clean.pdf
$ICCM
This higher risk patient population included patients with metastatic disease and tumors of up to 4 centimeters in diameter, as compared to our ICE3 study population with early-stage disease and tumors smaller than 2 centimeters in diameter, indicating a very different recurrence rate. Importantly, it further informs and supports the use cases of ProSense® across a broader range of breast cancer diagnoses, from newly diagnosed early-stage to metastatic and recurrent disease,"
92% non recurrence rate for higher risk later stage breast cancer with tumors twice the size 4 centimeters is remarkable. Someone is trying to steal shares from the low brow. 97% tumor free for early stage breast cancer with tumors 2 centimeters in diameter with 5 years of FOLLOW UP DATA.
$ICCM
European Study Provides More Evidence Supporting IceCure's ProSense® is Safe & Effective Cryoablation Treatment for Metastatic and Recurrent Breast Cancer
Prior Studies where for early stage breast cancer now there is incredible data for dealing with later stage and higher risk breast cancer patients. This is big news it moves when it moves I will keep adding at these levels!
Now have superior data on higher risk breast cancer patients!
Professor Vogl commented, "Liquid Nitrogen-based cryoablation was found to be a safe local treatment for breast cancer, with a low complication rate—in fact, none were observed in the study. We experienced a very high complete ablation rate of 100%.
Treating higher risk breast cancer patients makes ICCM platform more dynamic plus treating Lung, Kidney and Bone cancer patients with cryoblast. Giving options for patients who don't want surgery or radiation treatment with these incredible data points and 100% patient and Dr satisfaction using ICCM technology IceCure will be valued closer to PLSE market cap which is a Billion dollars.[
Independent, third-party data published in highly influential peer-reviewed journal, Cancers, concluded cryoablation with ProSense® is a safe, local treatment for breast cancer with low complication rate, high complete ablation rate and satisfactory overall survival (OS), progression free survival (PFS) and local tumor control.
$ICCM
Gets Past $2.00+ then $10.00+ in the play Charts says it all.
Killing all kinds of cancers with follow up Data on patients for 5 years and counting.
This stock should be trading 10-30x the current market cap more inline with Pulse Bio Sciences a Billion dollar market cap that has no revenue and is doing just cosmetic dermatology skin treatments.That stock was trading around a dollar a few years ago.
IceCure will make some people hyper wealthy.
$ICCM
“Cryoablation is a procedure that we know is safe, efficacious, cost effective and cosmetically superior to surgical removal. IceCure has improved upon the technology and developed a system optimized for breast fibroadenoma. My patients have been very happy with the short, painless procedure, and the ability to return to normal activity immediately.”
Andrew Kenler, MD, FACS
Independent Study Results in Japan Demonstrate Zero (0%) Breast Cancer Local Recurrence 5 Years Following Treatment with IceCure's ProSense®, Adding to Continued Positive Data Published Globally
https://www.prnewswire.com/il/news-releases/independent-study-results-in-japan-demonstrate-zero-0-breast-cancer-local-recurrence-5-years-following-treatment-with-icecures-prosense-adding-to-continued-positive-data-published-globally-302137926.html
$ICCM
IceCure non invasive treatment freezing cancers compared to surgery including breast cancer, Lung cancer, Kidney cancer Fibroadenoma and Palliative care.
I was in Pulse around the $1.75 range and believe IceCure has tremendous growth approved in 15 countries. FDA approval Q4 or early Q1 5 year follow up Data with 100% patient and doctor approval ratings. Over 55% insider ownership. No warrants or debt. 96% non recurrence rate for early stage malignant breast cancer.
RSI 32 Oversold.
June 2024 IceCure Business Presentation.
https://d1io3yog0oux5.cloudfront.net/_1427e4e7e9d44c0c61187db90d33f6f4/icecuremedical/db/2291/21959/pdf/IceCure+Company+Presentation+-+June+2024+-+Final+Clean.pdf
$ICCM
Talk about timing,
"https://ih.advfn.com/stock-market/NASDAQ/icecure-medical-ICCM/stock-news/93980503/fda-to-convene-advisory-panel-for-review-of-icecur"
Boing X 2
|
Followers
|
18
|
Posters
|
|
|
Posts (Today)
|
0
|
Posts (Total)
|
254
|
|
Created
|
01/20/20
|
Type
|
Free
|
| Moderators | |||
AI
